{"id":63756,"date":"2023-07-13T10:41:29","date_gmt":"2023-07-13T05:11:29","guid":{"rendered":"http:\/\/finservwealth.com\/usfda-accepts-dr-reddy39s-biologics-license-application-for-review-stock-dips\/"},"modified":"2023-07-13T10:41:29","modified_gmt":"2023-07-13T05:11:29","slug":"usfda-accepts-dr-reddy39s-biologics-license-application-for-review-stock-dips","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/usfda-accepts-dr-reddy39s-biologics-license-application-for-review-stock-dips\/","title":{"rendered":"USFDA accepts Dr Reddy#39;s Biologics License Application for review; stock dips"},"content":{"rendered":"<p> Dr. Reddy\u00e2\u20ac\u2122s rituximab biosimilar has already been approved for marketing in India and over 25 emerging markets.<\/p><div id=\"finse-1809340168\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/usfda-accepts-dr-reddy39s-biologics-license-application-for-review-stock-dips_17110431.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Dr. Reddy\u00e2\u20ac\u2122s rituximab biosimilar has already been approved for marketing in India and over 25 emerging markets. Dr. Reddy\u00e2\u20ac\u2122s rituximab biosimilar has already been approved for marketing in India and over 25 emerging markets.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/usfda-accepts-dr-reddy39s-biologics-license-application-for-review-stock-dips_17110431.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> Dr. Reddy\u00e2\u20ac\u2122s rituximab biosimilar has already been approved for marketing in India and over 25 emerging markets.<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/usfda-accepts-dr-reddy39s-biologics-license-application-for-review-stock-dips_17110431.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Dr. Reddy\u00e2\u20ac\u2122s rituximab biosimilar has already been approved for marketing in India and over 25 emerging markets. Dr. Reddy\u00e2\u20ac\u2122s rituximab biosimilar has already been approved for marketing in India and over 25 emerging markets.\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/usfda-accepts-dr-reddy39s-biologics-license-application-for-review-stock-dips_17110431.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> Dr. Reddy\u00e2\u20ac\u2122s rituximab biosimilar has already been approved for marketing in India and over 25 emerging markets.<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-63756","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2022\/200x200\/D\/Dr_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/63756","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=63756"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/63756\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=63756"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=63756"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=63756"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}